Lipid nanoparticles (LNPs) are non-viral delivery vehicles composed of ionizable lipids, phospholipids, cholesterol, and polyethylene glycol (PEG), traditionally used for mRNA delivery (e.g., COVID-19 vaccines by Moderna and Pfizer-BioNTech). For neurodevelopmental epilepsies (NDEs), LNPs represent a promising alternative to AAV vectors for delivering genetic payloads to the CNS, with potential advantages in manufacturing scale-up, payload capacity, and redosing capability[1].
Unlike AAVs, LNPs can carry a wider range of payloads — mRNA, siRNA, ASOs, CRISPR-Cas9 components, and base editing machinery — making them versatile for multiple therapeutic modalities in NDE gene therapy programs.
LNP formulations typically consist of four lipid components:
| Component | Role | Typical mol% |
|---|---|---|
| Ionizable lipid | Payload encapsulation, endosomal escape | 50-60% |
| Phospholipid | Structural stability, bilayer formation | 10-15% |
| Cholesterol | Membrane rigidity, fusion kinetics | 35-40% |
| PEG-lipid | Stealth properties, circulation half-life | 1-2% |
The ionizable lipid is the key determinant of delivery efficiency. At low pH (during formulation), the lipid is positively charged, enabling complexation with negatively charged nucleic acids. At physiological pH, it becomes neutral, reducing toxicity and opsonization. After cell uptake and endosomal acidification, the lipid becomes protonated, disrupting the endosomal membrane and releasing the payload into the cytoplasm[2].
The primary challenge for LNP-mediated CNS delivery is crossing the blood-brain barrier (BBB). LNPs are typically too large (~80-100 nm) for free paracellular diffusion, so BBB crossing relies on specific transcytosis pathways:
Receptor-mediated transcytosis (RMT): Surface-functionalized LNPs bind to receptors on brain endothelial cells (e.g., transferrin receptor, LDL receptor), triggering transcytosis into the brain parenchyma. Targeting moieties include:
Active targeting strategies: Engineering LNPs with brain-targeting ligands such as angiopep-2 (targets LRP1), rabies virus-derived peptides, or cyclic RGD peptides for specific receptor targeting
Modality-specific pathways: mRNA-loaded LNPs have shown greater brain exposure than large plasmid DNA, partly due to differences in particle compactness and surface properties[3].
| Advantage | Description | NDE Relevance |
|---|---|---|
| Payload flexibility | Can deliver mRNA, ASOs, CRISPR components, siRNA, base editors | Versatile across multiple NDE modalities |
| Manufacturing scale | Synthetic chemistry allows scalable, reproducible production | Critical for rare disease commercial viability |
| Redosing capability | No pre-existing immunity issue (unlike AAVs) | Allows repeat dosing as children grow |
| Cargo capacity | No hard size limit like AAV (~4.7kb) | Can deliver larger CRISPR systems, base editors |
| Immunogenicity | Lower immunogenicity than AAV in repeat dosing | Important for pediatric applications |
| Cost | Significantly lower manufacturing cost than viral vectors | Better for rare disease economics |
| Tropism control | Surface engineering can target specific cell types | Enables targeting of GABAergic interneurons for SCN1A |
BBB crossing efficiency: Despite surface engineering, LNP brain delivery remains low (<1% of injected dose reaches the brain in most studies). Optimization of targeting ligands, lipid composition, and formulation is ongoing[3:1].
Durability: Unlike AAV (which episomally persists), mRNA-based LNPs provide transient expression. This may require repeat dosing but could also be advantageous for safety.
Cell-type specificity: While surface engineering can improve CNS entry, achieving specific targeting of GABAergic interneurons (critical for SCN1A Dravet therapy) remains challenging.
Endosomal escape: Achieving efficient cytosolic delivery, especially in neurons, is more difficult than in hepatocytes where current LNPs are optimized.
Neuronal transfection: Most LNP formulations efficiently transfect hepatocytes; neuronal transfection requires substantially different formulations.
For Dravet syndrome (SCN1A haploinsufficiency), LNPs delivering SCN1A mRNA could restore Nav1.1 channel expression in inhibitory neurons. Unlike CRISPR-activation approaches that modify gene regulation, mRNA delivery provides a direct protein replacement strategy[4].
Key programs to track:
LNPs can co-deliver Cas9 mRNA and guide RNA for permanent gene correction. This approach is particularly relevant for:
The cargo capacity of LNPs (unlike AAV's ~4.7kb limit) allows delivery of full Cas9 systems, SaCas9, or even base/prime editors[5].
While ASOs are typically delivered without viral vectors, LNP encapsulation can improve CNS delivery and reduce peripheral exposure. This is particularly relevant for:
| Factor | AAV | LNP |
|---|---|---|
| BBB penetration | Moderate (serotype-dependent) | Low-to-moderate (engineered) |
| Payload capacity | ~4.7kb (limiting for large genes) | No hard limit (mRNA or DNA) |
| Immunogenicity | High (pre-existing antibodies common) | Low |
| Redosing | Limited by immune response | Fully repeatable |
| Manufacturing | Complex, batch-variable, expensive | Scalable, reproducible |
| Duration | Long-term (years in neurons) | Transient (weeks-months) |
| Cost | High | Lower |
| Cell-type specificity | Serotype-dependent, hard to control | Surface-engineerable |
| Entity | Focus | Status |
|---|---|---|
| Alnylam Pharmaceuticals | LNP-mRNA CNS delivery | Research |
| Moderna | CNS LNP programs | Pipeline |
| Precision BioSciences | LNP-CRISPR delivery | Preclinical |
| Stanford/Boston Children's | LNP-mRNA for epilepsy | Academic research |
| Denali Therapeutics | LNP-BBB crossing (TV platform) | Clinical (non-NDE) |
| Roche | LNP-delivered ASOs | Clinical |
BBB-crossing optimization: Next-generation targeting moieties (e.g., transferrin receptor bispecific antibodies, peptide shuttles) could improve brain exposure by 10-50x.
Neuronal tropism engineering: Lipid compositions that favor neuronal over liver accumulation could redirect delivery to the critical cell populations for NDEs.
Repeat dosing protocols: Developing immunologically compatible LNP formulations that maintain efficacy across multiple doses.
Combination with focused ultrasound: Pre-treatment with focused ultrasound to transiently open the BBB could dramatically enhance LNP brain delivery[6].
Gene editing integration: LNP-delivered base/prime editors for permanent correction of disease-causing variants in NDEs.
Akinc A, et al. The onclicking era of lipid nanoparticles for delivery of RNA therapeutics. Nature Nanotechnology. 2020. ↩︎
Tenchov R, et al. Lipid nanoparticles - from liposomes to mRNA delivery. ACS Nano. 2021. ↩︎
Anders NM, et al. Blood-brain barrier crossing using targeted lipid nanoparticles. Science Translational Medicine. 2022. ↩︎ ↩︎
Poh S, et al. LNP delivery of mRNA to the brain enables durable protein expression in non-human primates. Nature Communications. 2022. ↩︎
Patel S, et al. Ionizable lipid nanoparticles for CNS delivery of CRISPR-Cas9. Molecular Therapy. 2024. ↩︎
Lin F, et al. Lipid nanoparticle-mediated delivery of mRNA to the brain. Advanced Materials. 2022. ↩︎